Table 2.
Baseline population characteristics.
| Variable | N = 28 |
|---|---|
| Female gender | 3 (10) |
| Age (years) | 67 ± 8 |
| Waist (cm) | 103 ± 9 |
| BMI (kg/m2) | 28 ± 4 |
| Diabetes mellitus | |
| Insulin treated | 3 (11) |
| OHD treated | 20 (71) |
| OHD and Insulin | 5 (18) |
| Mean duration of diabetes mellitus (years) | 12 ± 6 |
| Dyslipidemia | 25 (86) |
| Hypertension | 25 (86) |
| Smoking | 7 (24) |
| Clinical presentation | |
| Stable angina | 24 (86) |
| Unstable angina | 4 (14) |
| Previous MI | 7 (25) |
| Previous PCI | 15 (53) |
| Previous CABG | 6 (21) |
| LVEF (%) | 56 ± 5 |
| Medications | |
| Aspirin | 28 (100) |
| Clopidogrel | 28 (100) |
| ACEi/ARBs | 14 (50) |
| β-blockers | 17 (59) |
| Statins | 21 (74) |
| Calcium channel blockers | 10 (34) |
| Oral hypoglycemic agents | 25 (89) |
| Biguanides | 12 (43) |
| Sulphonylurea | 6 (21) |
| Biguanides and Sulphonylurea | 7 (25) |
Values are given as mean ± SD or n (%). ACEi/ARBs: angiotensin converting enzyme inhibitors/angiotensin converting enzyme blockers; BMI: body mass index; CABG: coronary artery bypass graft; IGT: impaired glucose tolerance; LVEF: left ventricular ejection fraction; MI: myocardial infarction; OHD: oral hypoglycemic drugs; PCI: percutaneous coronary intervention.